Statins

Statins has been studied in 2,082 papers since 1993: 207 trials and 920 observational studies in people, 195 in animals, 67 in cells, 578 reviews; 1,010 in the past year. The newest story, Nov 18, 2026: “Statins not linked to lower dementia risk in older male veterans”.

Intervention

2,082 papers study it820 more mention it2,397 findingsUpdated

Research on it is growing 22% faster than aging research as a whole: 28 papers in the latest year counted

460 new papers in 30 daysSee all 2,874 papers on statins

At a glance

Statin use is linked with lower mortality in critically ill stroke patients, while independent labs reproduce simvastatin lifespan extension in flies and reduced senescence with pravastatin in human cells. A contrasting result shows simvastatin shortens fly lifespan. Some papers declare ties to developers, and some authors work at companies.

2,397 findings in 1,205 papers from 1993 to 2026, 243 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 545 independent labs in 68 countries; 1,470 trials, 270 about aging, 746 with no results posted.

“Statins across intensities and statin–ezetimibe therapy were not associated with increased overall or site-specific cancer risk.”
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trialsESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4162

267 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 545 independent labs in 68 countries
  • 267 findings against
  • 1,470 trials, 270 about aging, 746 with no results posted
  • Funders: National Institutes of Health and others
  • 215 of 2,092 findings with company ties
  • 361 of 1,470 trials sponsored by its developers
  • Human trial206
  • Humans909
  • Animals188
  • Model organisms4
  • Cells65
  • In silico34

120 studies gave statins to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cisplatin-induced ototoxicity41.38% of the case group versus 44.4% of the control group experienced ototoxicity

Randomized trial56 peoplePatients with solid tumors receiving cisplatin chemotherapyDrug design, development and therapy, Nov 7, 2026

up: Increases proteomic response140 significant proteins in G1 versus 68 in G2+G3; FDR q<0.05

up: Increases CALCA/CGRPFDR q=0.044

Randomized trial133 peopleConfirmed statin myalgia compared with nocebo and tolerant controlsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

no change: Has no effect on cancer incidencemoderate-intensity vs high-intensity RR 1.0 (95% CrI 0.68–1.5)

no change: Has no effect on cancer-related mortalityRR 1.1 (95% CrI 0.94–1.2)

no change: Has no effect on site-specific cancer risk

Review of trialsmedian follow-up ~4 years219,006 people pooledBothAcross statin intensities and statin–ezetimibe therapyESC Congress 2026 abstract, Oct 26, 2026

down: Lowers the risk of cardiovascular diseaseHR 0.70, 95% CI 0.61–0.82, P<0.001

no change: Has no effect on disability-free survivalHR 0.94, 95% CI 0.84–1.05, P = 0.25

Randomized trial5.9 years9,971 peopleBoth74.7±4.5 yearsOlder adultsThe New England journal of medicine, Aug 29, 2026

down: Decreases endocan

down: Decreases endoglin

down: Decreases endocan

Treated cohortmedian 12 (IQR 8–12) weeks128 peoplewomenmedian age 60 years (IQR 56–64 years)Postmenopausal women aged up to 70 yearsBiomedicines, Aug 27, 2026

What did mouse lifespan tests of statins find?

NIA ITP

The NIA Interventions Testing Program ran 2 arms in 2006; the change in median lifespan ran from −4% to +4%.

What did other lifespan studies of statins find?

DrugAge

DrugAge records 7 results from 4 papers: 5 in C. elegans, 1 in B. manjavacas and 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of statins find?

329

Studies of statins measured 329 outcomes; the most studied are mortality (22 studies), inflammation (14) and LDL-C (7).

Mortality

downin humans14no changein humans7upin O. niloticus1RR 0.43–0.83

22 studies
  1. Statins decrease mortality in humans (pre-ICH statin use) (aOR 0.46, 95% CI 0.26–0.80).

    “Pre-ICH statin use was associated with lower 6-month mortality (aOR 0.46, 95% CI 0.26–0.80; p = 0.007).”

    Human trialpre-ICH statin use6 monthsn = 6,254

    Association between statin treatment and outcomes after acute intracerebral hemorrhage in the third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial study

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  2. Statins showed no clear effect on mortality in humans (primary prevention of ASCVD) (-0.68% (95% CI -3.95 to 2.60)).

    “The absolute difference in all-cause mortality between groups was -0·68% (95% CI -3·95 to 2·60).”

    Human trialprimary prevention of ASCVD36 monthsn = 1,160

    Stopping preventive statins met the trial’s death-risk limit

    The lancet. Healthy longevity

  3. Statins decrease mortality in humans (STEMI patients undergoing primary PCI; pooled RCTs) (OR: 0.59, 95% CI: 0.36-0.98).

    “It was also associated with a reduction in all-cause mortality (OR: 0.59, 95% CI: 0.36-0.98).”

    Human trialSTEMI patients undergoing primary PCI; pooled RCTshigh-dose preloading before primary PCI

    Evaluating the benefits of high-dose statin preloading in ST-segment elevation myocardial infarction management: insights from a systematic review and meta-analysis

    Coronary artery disease

  4. Pravastatin protects against mortality in humans (moderately hypercholesterolemic, hypertensive, under full adherence) (RR 0.79 (0.68, 0.91), risk difference -3.0% (-4.9%, -1.3%)).

    “the risk ratio was 0.79 (0.68, 0.91) for death”

    Human trialmoderately hypercholesterolemic, hypertensive, under full adherence40 mg/day5 yearn = 9,741

    Trial reanalysis links pravastatin adherence to fewer deaths

    American journal of epidemiology

  5. Statins were not clearly linked with mortality in humans (11.9% vs 14.4%; RR 0.83, 95% CI 0.58-1.18; p=0.297).

    “At 3 years, statin initiation was not associated with lower all-cause mortality (11.9% vs 14.4%; RR 0.83, 95% CI 0.58-1.18; p=0.297)”

    HumansNewly documented incidental coronary artery calcium; statin initiation within 60 days versus no initiation, after propensity matching3 years

    Incidental Coronary Artery Calcification on Chest CT- Statin Treatment Gaps and Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

  6. Statins are linked with lower mortality in humans after TAVI (log-rank p=0.00325).

    “Statin use was associated with lower 5-year mortality overall and among patients aged ≥90 years (log-rank p=0.00325)”

    Humansafter TAVI5 years

    Statins are linked to better survival after TAVI across the oldest ages,: analysis from the multicenter TAVI registry

    ESC Congress 2026 abstract

  7. Statins are linked with lower mortality in non-cirrhotic patients with primary biliary cholangitis (HR 0.318, 95% CI 0.153-0.661).

    “significantly lower risk of all-cause mortality (HR=0.318; 95%CI 0.153-0.661, p=0.002)”

    Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

    Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis

    European journal of internal medicine

  8. Statins were not clearly linked with mortality in humans across the whole estimated risk spectrum in adults aged 70-89 without diabetes.

    “We did not observe a protective association with all-cause mortality across the whole estimated risk spectrum.”

    Humansacross the whole estimated risk spectrum in adults aged 70-89 without diabetesn = 167,360

    SCORE2-OP-guided statin initiation for primary prevention in adults aged 70-89 years without diabetes: evidence for age-specific risk thresholds

    European journal of preventive cardiology

  9. Statins are linked with lower mortality in humans after intracerebral hemorrhage (aOR 0.46, 95% CI 0.26-0.80).

    “pre-ICH statin use was associated with lower 6-month mortality (aOR 0.46, 95% CI 0.26-0.80)”

    Humansafter intracerebral hemorrhage6 months

    Association between statin treatment and outcomes after acute intracerebral hemorrhage in the third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial study

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  10. Statins were not clearly linked with mortality in humans (multivariable adjusted analysis in severe traumatic brain injury).

    “After adjusting for baseline differences, pre-injury statin use was not an independent predictor of mortality following multiple logistic regression.”

    Humansmultivariable adjusted analysis in severe traumatic brain injuryn = 816

    Severity Matters: Injury Severity May Limit the Protective Association of Pre-injury Statin Therapy After Traumatic Brain Injury

    The American surgeon

All 23

Inflammation

downin humans3downin mice3downin reviews3downin rats2+4

14 studies
  1. Atorvastatin inhibits inflammation in humans (decompensated liver cirrhosis).

    “Inflammatory biomarkers demonstrated a marked response to atorvastatin therapy.”

    Human trialdecompensated liver cirrhosissix monthsn = 110

    Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial

    Scientific reports

  2. Atorvastatin inhibits inflammation in humans (decompensated cirrhosis) (P < 0.05).

    “These clinical improvements were mirrored by significant reductions in MDA, NF-κB, LPS, and zonulin levels (P < 0.05)”

    Human trialdecompensated cirrhosis20 mg/daysix monthsn = 100

    Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial

    Scientific reports

  3. Statins were not clearly linked with inflammation in humans (type 2 diabetes hospitalized for COVID-19, multivariable adjustment).

    “No independent association with inflammatory markers was confirmed”

    Humanstype 2 diabetes hospitalized for COVID-19, multivariable adjustment

    Association Between Statin Use, Cytokine Storm, and Clinical Outcomes in COVID-19 Patients with Diabetes

    Biomedicines

  4. Atorvastatin decreases inflammation in humans.

    “the available evidence supports the combined lipid-lowering and anti-inflammatory effects of atorvastatin across diverse patient populations”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

  5. Statins inhibit inflammation in humans.

    “In addition to lowering low-density lipoprotein cholesterol, statins influence inflammatory signaling”

    Review

    Inflammation, Statin Pleiotropy, and Cardiovascular Prevention in Women: Established Evidence, Biological Plausibility, and Knowledge Gaps

    Journal of cardiovascular development and disease

  6. Rosuvastatin decreases inflammation in rats (burn wound) (P < 0.01).

    “Histopathology revealed a statistically significant reduction in inflammatory infiltration, coagulative necrosis, and microhemorrhage (P < 0.01).”

    Animalsburn woundcreamskinmalesn = 90

    Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model

    World journal of experimental medicine

  7. Atorvastatin decreases inflammation in mice (female AS mouse models).

    “reduces inflammatory signaling, and enhances plaque stabilization in female AS mouse models.”

    Animalsfemale AS mouse modelsfemales

    A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis

    Nature communications

  8. Atorvastatin decreases inflammation in rats (zoledronic acid-induced MRONJ).

    “It also reduced inflammation”

    Animalszoledronic acid-induced MRONJHPMC and graphene oxide hydrogel loaded with ATVjaw1.2%three weeksfemales

    Characterization and therapeutic effects of an atorvastatin graphene oxide hydrogel on medication induced osteonecrosis of the jaws in female rats

    Tissue & cell

  9. Simvastatin decreases inflammation in hPDLSCs.

    “Both SIM concentrations (0.1 and 1 μM) significantly reduced the basal expression of these inflammatory cytokines compared to that in the control group (p < 0.001).”

    Cellsin hPDLSCs0.1 and 1 μM12 monthsmalesn = 24

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

  10. Simvastatin decreases inflammation in vitro.

    “Both SIM concentrations (0.1 μM and 1 μM) significantly reduced basal pro-inflammatory cytokine expression (TNF-α and IL-6).”

    Cellsin vitroperiodontal ligament stem cells0.1 μM and 1 μM

    Simvastatin Enhances Stem Cell Osteogenesis and Reduces Peri-Implant Bone Loss: An In Vitro and a Randomized Clinical Study

    Pharmaceuticals (Basel, Switzerland)

All 16

More on Inflammation

LDL-C

downin humans6downin reviews1−55% to −45%

7 studies
  1. Statins are linked with lower LDL-C in humans.

    “Despite a modest dose-response trend in absolute LDL-C reduction, interindividual variability was profound”

    Humansone year

    Real-world variability and factors associated with individual low-density-lipoprotein cholesterol response to different doses of atorvastatin, rosuvastatin, and simvastatin in 28,647 Chinese patients

    Atherosclerosis

  2. Statins are linked with lower LDL-C in humans (statin therapy followed over the study period).

    “A progressive improvement in lipid profile parameters was observed over the study period, with reductions in total cholesterol, LDL-C, and TG”

    Humansstatin therapy followed over the study period6 months

    A STUDY TO ASSESS THE STATIN THERAPY ADHERENCE AND ITS IMPACT ON LIPID PROFILE AND CARDIOVASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIA

    World Journal of Current Medical and Pharmaceutical Research

  3. Statins are linked with lower LDL-C in humans (combined with ezetimibe) (<35 mg/dL).

    “LDL-C decreased to < 35 mg/dL and remained consistently suppressed.”

    Humanscombined with ezetimibehigh-intensity2 yearsfemales

    Plaque Morphology-Dependent Regression of Tandem Coronary Plaques Under Intensive Lipid-Lowering Therapy

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

  4. Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).

    “In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”

    Humansdyslipidemia12-weekn = 55

    Association of polymorphisms of ApoE, ApoA1, PCSK9 with LDL-C modification following Atorvastatin therapy in dyslipidemic patients

    Research SquarePreprint

  5. Statins are linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-45%).

    “statin (45%)”

    Humansin multidisciplinary cardiometabolic clinic patients

    Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol

    Internal medicine journal

  6. Statins decrease LDL-C.

    “consequently reducing low-density lipoprotein cholesterol (LDL-C) levels”

    Review

    Beyond LDL-C reduction: molecular pleiotropy and emerging therapeutic roles of statins

    Naunyn-Schmiedeberg's archives of pharmacology

  7. Statins decrease LDL-C in humans.

    “Intensive lipid lowering remains key, with high-intensity statins, ezetimibe, and PCSK9 inhibitors used sequentially to achieve very low LDL-C targets”

    Reviewhigh-intensity

    Key advances in secondary prevention after coronary artery bypass grafting

    Current opinion in cardiology

More on LDL-C

LDL cholesterol

downin humans6

6 studies
  1. Statins are linked with lower LDL cholesterol in humans (around the first recorded prescription date) (donut estimates vary from - 1.00 to - 1.72 mmol/L).

    “Statin analyses show a local downward LDL discontinuity around the first recorded prescription date”

    Humansaround the first recorded prescription date

    Event-time regression discontinuity for biomedical data: LATT estimation and covariate distribution tests

    American journal of epidemiology

  2. Atorvastatin decreases LDL cholesterol in humans.

    “Atorvastatin exhibits several notable features: a titratable dosing strategy that spans all risk categories, robust LDL-C lowering”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

  3. Rosuvastatin decreases LDL cholesterol in humans (Highest-ranked regimen for LDL cholesterol reduction in the network meta-analysis) (P-score 0.9906).

    “For LDL-C reduction, rosuvastatin 10 mg ranked highest (P-score 0.9906)”

    ReviewHighest-ranked regimen for LDL cholesterol reduction in the network meta-analysis10 mg

    Dose-Dependent Lipid Effects and Safety of Pitavastatin versus Other Statins in Dyslipidemia: A Systematic Review and Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  4. Statins decrease LDL cholesterol in patients with systemic lupus erythematosus (MD -35.49 mg/dL).

    “LDL cholesterol (MD -35.49 mg/dL; 95% CI -57.14, -13.83; p < 0.01)”

    Reviewin patients with systemic lupus erythematosus18.5 monthsn = 668

    Effects of statin therapy on atherosclerosis progression, inflammation and lipid profiles in patients with systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials

    Autoimmunity reviews

  5. Statins decrease LDL cholesterol in humans (hypercholesterolemia or mixed dyslipidemia).

    “Statins remain the primary therapy to reduce LDL-C”

    Reviewhypercholesterolemia or mixed dyslipidemia

    Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia

    Expert opinion on pharmacotherapy

  6. Lovastatin decreases LDL cholesterol in humans.

    “Our findings indicate that monacolin K-containing supplements are effective in lowering lipid levels, particularly low-density lipoprotein cholesterol (LDL-C).”

    Reviewmonacolin K-containing supplementsplasma

    Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials

    Endocrinology, diabetes & metabolism

More on LDL cholesterol

Angiogenesis

upin rats2no changein F. catus1upin human cells1downin human cells1+1+65%

6 studies
  1. Simvastatin activates angiogenesis in human cells (SHED-HUVEC co-culture).

    “Simvastatin also elevated the expression of angiogenic regulatory factors in SHED, promoting more extensive reticular structure formation by HUVEC through paracrine interactions between SHED and HUVEC.”

    CellsSHED-HUVEC co-culture

    Coordinated effect of simvastatin-induced osteogenesis and angiogenesis mediated by Wnt/β-catenin signaling pathway on vascularized bone tissue formation

    Journal of translational medicine

  2. Rosuvastatin increases angiogenesis in rats (burn wound) (P = 0.012).

    “Conversely, statistically significant increases in neovascularization (P = 0.012) and fibroblastic reactions (P = 0.023) were noted.”

    Animalsburn woundcreamskinmalesn = 90

    Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model

    World journal of experimental medicine

  3. Simvastatin inhibits angiogenesis in human cells (high concentrations, alone or combined with alendronate) (near abolishment).

    “The same exposure induced near abolishment of secreted levels of cytokines affecting angiogenesis, such as VEGF, IL-6, IL-8, and MCP-1”

    Cellshigh concentrations, alone or combined with alendronategingival fibroblasts and osteoblasts

    Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues

    Acta odontologica Scandinavica

  4. Rosuvastatin increases angiogenesis (burn wounds).

    “targeted action on the endothelium, improving microcirculation and promoting angiogenesis.”

    Reviewburn wounds

    Effects of rosuvastatin treatment and other statins on burn wound healing

    World journal of methodology

  5. Atorvastatin increases angiogenesis in rats (zoledronic acid-induced MRONJ) (+65.0%).

    “enhanced blood vessel formation (+ 65.0%)”

    Animalszoledronic acid-induced MRONJHPMC and graphene oxide hydrogel loaded with ATVjaw1.2%three weeksfemales

    Characterization and therapeutic effects of an atorvastatin graphene oxide hydrogel on medication induced osteonecrosis of the jaws in female rats

    Tissue & cell

  6. Simvastatin showed no clear effect on angiogenesis in F. catus (ovarian autotransplantation).

    “There was no significant difference in the vascularization area among the groups on any post-transplant day.”

    Animalsovarian autotransplantationovary

    Simvastatin and EPO in feline ovarian grafting: Distinct effects on cell and follicle survival

    Theriogenology

More on Angiogenesis

Oxidative stress and ROS signaling

upin C. albicans cells1downin cells1upin O. niloticus1downin rats1+1

5 studies
  1. Statins decrease oxidative stress and ROS signaling.

    “they exhibit anti-inflammatory effects, reduce oxidative stress”

    Review

    The impact of statin therapy on cognitive functioning - current state of knowledge

    Archives of Psychiatry and Psychotherapy

  2. Atorvastatin induces oxidative stress and ROS signaling in O. niloticus.

    “Lipid peroxidation increased only at 0.2 and 0.5 mg/kg of ATV, suggesting oxidative damage at these concentrations.”

    Animals0.2 and 0.5 mg/kg45 days

    Evaluation of Toxicity and Oxidative Stress Following Chronic Exposure to Lipid-Lowering Drug Atorvastatin Using Nile Tilapia

    Research SquarePreprint

  3. Rosuvastatin decreases oxidative stress and ROS signaling in cells (ox-LDL-induced).

    “rosuvastatin suppressed ox-LDL-induced endothelial oxidative stress”

    Cellsox-LDL-inducedendothelial cells

    Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway

    PloS one

  4. Simvastatin increases oxidative stress and ROS signaling in C. albicans cells (Strain MTCC 854) (4-fold increase).

    “ROS generation assay revealed an 18-fold increase in oxidative stress with Atorvastatin, while Simvastatin showed only a 4-fold increase.”

    CellsStrain MTCC 854

    Repurposing statins as potential antifungal agents for Candida albicans: in-vitro and in-silico approach

    Future microbiology

  5. Atorvastatin increases oxidative stress and ROS signaling in C. albicans cells (Strain MTCC 854) (18-fold increase).

    “ROS generation assay revealed an 18-fold increase in oxidative stress with Atorvastatin, while Simvastatin showed only a 4-fold increase.”

    CellsStrain MTCC 854

    Repurposing statins as potential antifungal agents for Candida albicans: in-vitro and in-silico approach

    Future microbiology

  6. Pravastatin decreases oxidative stress and ROS signaling in hyperlipidemic rats compared to marketed pravastatin tablets.

    “In vivo evaluation in hyperlipidemic Wistar rats showed significantly improved lipid profiles and reduced oxidative stress compared to marketed pravastatin tablets.”

    Animalsin hyperlipidemic rats compared to marketed pravastatin tablets

    Pravastatin-Loaded nanostructured lipid carriers: formulation optimization and in-vivo assessment for antihyperlipidaemic effect in rats

    Journal of drug targeting

More on Oxidative stress and ROS signaling

C-reactive protein

downin humans5

5 studies
  1. Rosuvastatin decreases C-reactive protein in humans (Compared with atorvastatin after excluding one outlying study) (MD −0.16 mg/L; 95% CI −0.28 to −0.03; p = 0.01).

    “rosuvastatin demonstrated a greater CRP reduction (MD –0.16 mg/L; 95% CI –0.28 to –0.03; p = 0.01)”

    ReviewCompared with atorvastatin after excluding one outlying study

    Comparative Effects of Atorvastatin and Rosuvastatin on Randomized Head-to-Head Trials: A Systematic Review and Meta-Analysis of Inflammatory Biomarker Changes

    AHA Scientific Sessions 2026 abstract

  2. Rosuvastatin decreases C-reactive protein in humans (Acute coronary syndrome; compared with atorvastatin) (WMD 4.08; 95% CI 1.53–6.63).

    “rosuvastatin may provide greater short-term reductions in CRP and modest increases in HDL-C compared with atorvastatin”

    ReviewAcute coronary syndrome; compared with atorvastatin≤1 month

    Effect of Atorvastatin and Rosuvastatin on Lipid Parameters and Inflammatory Biomarkers in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

    Cardiology in review

  3. Rosuvastatin decreases C-reactive protein in humans after excluding one outlier (MD: -0.16 mg/L).

    “rosuvastatin showed a greater reduction (MD: - 0.16 mg/L; 95% CI: - 0.28 to - 0.03; p = 0.01; I2 = 63%).”

    Reviewafter excluding one outliern = 6,148

    Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials

    BMC cardiovascular disorders

  4. Statins decrease C-reactive protein in patients with systemic lupus erythematosus (MD -0.61 mg/L).

    “Statin therapy significantly reduced hs-CRP (MD -0.61 mg/L; 95% CI -1.12, -0.11; p = 0.017)”

    Reviewin patients with systemic lupus erythematosus18.5 monthsn = 668

    Effects of statin therapy on atherosclerosis progression, inflammation and lipid profiles in patients with systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials

    Autoimmunity reviews

  5. Statins decrease C-reactive protein in humans (parallel controlled trials) (SMD -1.45, 95% CI -2.84 to -0.07).

    “Statins lowered CRP in both controlled before-after studies (standardised mean difference (SMD)=-0.38, 95% CI -0.73 to -0.03; p=0.032) and parallel controlled trials (SMD=-1.45, 95% CI -2.84 to -0.07; p=0.040).”

    Reviewparallel controlled trials

    Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers

    Lupus science & medicine

More on C-reactive protein

Cognitive function

upin humans1no changein humans1downin humans1upin mice1+1

5 studies
  1. Atorvastatin improves cognitive function in humans (β = 0.980, P < 0.001).

    “atorvastatin was an independent protective factor for cognitive recovery (β = 0.980, P < 0.001).”

    Human trial20 mg nightly6 monthsn = 67

    Atorvastatin accelerates hematoma absorption and ameliorates cognitive impairment in patients with chronic subdural hematoma complicated by cognitive dysfunction: a retrospective analysis

    Frontiers in pharmacology

  2. Atorvastatin showed no clear effect on cognitive function in humans (0.1 units (95% CI, -0.3 to 0.03)).

    “with no significant group differences (0.1 units; 95% CI, -0.3 to 0.03; P = .12)”

    Human trialwithout dementia and with hypertension, family history of dementia, and/or self-reported subjective cognitive decline24 monthsn = 480

    Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial

    JAMA neurology

  3. Statins are linked with worse cognitive function in Parkinson's disease patients.

    “statin use was associated with a faster cognitive decline among PD patients during longitudinal follow-up”

    Humansin Parkinson's disease patients

    Association of Statin use with Parkinson's Disease Progression in a Prospective Cohort Study and Multi-omics Analyses

    Journal of molecular neuroscience : MN

  4. Statins improve cognitive function (opioid tolerance/withdrawal and SUD models).

    “while enhancing neurotrophic signaling and cognitive outcomes”

    Reviewopioid tolerance/withdrawal and SUD models

    Preclinical evidence for statin modulation of analgesic tolerance and substance use disorders: a narrative review

    The American journal of drug and alcohol abuse

  5. Simvastatin improves cognitive function in mice (maternal separation).

    “Simvastatin in MS mice led to notable improvements in behaviour and cognition”

    Animalsmaternal separationhippocampus2.5, 5 and 10 mg/kg2 weeks

    Modulation of Neuroinflammation and Nitrite Imbalance in the Hippocampus by Simvastatin: Therapeutic Potential in Maternal Separation-Induced Autism Spectrum Disorder

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience

Major adverse cardiovascular events

no changein humans2downin humans2−35% reductionRR 0.89

4 studies
  1. Atorvastatin showed no clear effect on major adverse cardiovascular events in humans (noncardiac surgery in patients with RCRI >= 1).

    “it did not translate into a reduction of short-term clinical cardiovascular events.”

    Human trialnoncardiac surgery in patients with RCRI >= 180 mg24 hours preoperatively

    The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial

    Research in heart yield and translational medicine

  2. Statins were not clearly linked with major adverse cardiovascular events in humans (17.1% vs 19.4%; RR 0.89, 95% CI 0.66-1.19; p=0.412).

    “or MACE (17.1% vs 19.4%; RR 0.89,95% CI 0.66-1.19; p=0.412).”

    HumansNewly documented incidental coronary artery calcium; statin initiation within 60 days versus no initiation, after propensity matching3 years

    Incidental Coronary Artery Calcification on Chest CT- Statin Treatment Gaps and Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

  3. Pitavastatin decreases major adverse cardiovascular events in humans (people living with HIV receiving antiretroviral therapy) (approximately 35% reduction).

    “pitavastatin therapy reduced major adverse cardiovascular events by approximately 35% in people living with HIV receiving antiretroviral therapy”

    Reviewpeople living with HIV receiving antiretroviral therapy

    Interleukin-Driven Inflammation and Cardiovascular Risk in People Living with HIV: Mechanisms, Biomarkers, and Emerging Preventive Strategies

    Medical sciences (Basel, Switzerland)

  4. Statins decrease major adverse cardiovascular events in humans (diabetes).

    “high-intensity statin therapy associated with significant reductions in major adverse cardiovascular events (MACE).”

    Reviewdiabetes

    Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes

    Clinical medicine insights. Endocrinology and diabetes

Rhabdomyolysis

upin humans4

4 studies
  1. Rosuvastatin induces rhabdomyolysis in humans after switching from atorvastatin 20 mg daily to rosuvastatin 40 mg daily (CPK 73,347 U/L, creatinine 12.48 mg/dL).

    “He had recently been switched from atorvastatin 20 mg daily to rosuvastatin 40 mg daily, 3 weeks prior. Laboratory results showed markedly elevated CPK (73,347 U/L), AST (1127 U/L), ALP (246 U/L), and creatinine (12.48 mg/dL), consistent with severe rhabdomyolysis causing AKI.”

    Human trialafter switching from atorvastatin 20 mg daily to rosuvastatin 40 mg daily40 mg daily3 weeksmales

    C49-27 A Double Hit: Statin-induced Rhabdomyolysis Requiring Dialysis Complicated By Hemodialysis-induced Acute Coronary Syndrome

    American Journal of Respiratory and Critical Care Medicine

  2. Atorvastatin induces rhabdomyolysis in humans.

    “The cause for myopathy, rhabdomyolysis, and liver injury was ascertained to be Atorvastatin”

    Human trialfemales

    A Case Report of Statin-induced Myopathy, Rhabdomyolysis and Liver Injury (SILI): A Rare but Potentially Life-threatening Adverse Effect

    Euroasian journal of hepato-gastroenterology

  3. Statins are linked with rhabdomyolysis in humans.

    “we present a case of statin-induced rhabdomyolysis diagnosed and managed at Hanoi Medical University Hospital”

    Humansn = 1

    Statin-induced rhabdomyolysis: A case report

    Tạp chí Nghiên cứu Y học

  4. Statins are linked with rhabdomyolysis in humans (CK of 23,203 U/L).

    “Here, we report the case of a 77-year-old woman who presented with myalgias and weakness and was subsequently found to have a CK of 23,203 U/L, transaminitis, and acute kidney injury”

    Humansseven yearsfemales

    A Case of Statin-Induced Rhabdomyolysis After Seven Years of Statin Therapy

    Cureus

More on Rhabdomyolysis

Total cholesterol

downin humans2no changein humans1

3 studies
  1. Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).

    “atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”

    Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks

    Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial

    Narra X

  2. Statins are linked with lower total cholesterol in humans (TC 3.70 vs 4.18 mmol/L; LDL-C 1.88 vs 2.17 mmol/L).

    “Statin therapy significantly reduced total cholesterol (TC: 3.70 ± 0.88 vs. 4.18 ± 0.84 mmol/L, P = 0.004)”

    Humansstandard-dosestandard dose

    Analysis of the association between SLCO1B1 gene polymorphisms and coronary heart disease risk in southern Han Chinese population and statin responses in the elderly

    Frontiers in cardiovascular medicine

  3. Statins decrease total cholesterol in humans.

    “Statins remain the mainstay of pharmacotherapy for reducing concentrations of total cholesterol and low-density lipoproteins, as well as for preventing atherosclerotic cardiovascular disease.”

    Review

    Statins and safety: an evidence-based assessment of common beliefs about adverse effects with a focus on endocrinology practice

    Axis of endocrinology

More on Total cholesterol

Cancer-related mortality

no changein humans2RR 1.1

2 studies
  1. Statins showed no clear effect on cancer-related mortality in humans (moderate-intensity vs high-intensity statin therapy) (RR 1.1 (95% CrI 0.94–1.2)).

    “Compared with high-intensity statin therapy, RRs were 1.1 (95% CrI 0.94–1.2) for moderate-intensity”

    Human trialmoderate-intensity vs high-intensity statin therapyn = 203,995

    Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials

    ESC Congress 2026 abstract

  2. Statins were not clearly linked with cancer-related mortality in humans (without CHD).

    “Statin use was associated with lower all-cause, cardiac, and cancer-related mortality in older cancer survivors with CHD, but not with cancer-related mortality in those without CHD.”

    Humanswithout CHD

    Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease

    Archives of gerontology and geriatrics

Adverse events

no changein humans2

2 studies
  1. Statins showed no clear effect on adverse events in humans (74.0% vs 73.1%).

    “Adverse events occurred in 461 (73·1%) of 631 participants in the continuation group, and in 390 (74·0%) of 527 in the discontinuation group.”

    Human trial36 months

    Stopping preventive statins met the trial’s death-risk limit

    The lancet. Healthy longevity

  2. Atorvastatin showed no clear effect on adverse events in humans.

    “No clinically significant differences in adverse events were observed.”

    Human trialAdded to standard triple therapy versus standard triple therapy with placebo in patients with H. pylori infection40 mg once daily14 daysn = 138

    Efficacy of Standard Triple Therapy With or Without Statin in Helicobacter pylori Eradication: A Randomized Double-Blind Placebo-Controlled Trial

    Helicobacter

Body weight

downin humans1downin mice1

2 studies
  1. Atorvastatin decreases body weight in humans (fully adjusted model).

    “Atorvastatin was significantly associated with reductions in body weight (p=0.029)”

    Human trialfully adjusted model40 mg once daily12 weeks

    Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial

    Narra X

  2. Rosuvastatin decreases body weight in mice (high-fat diet-fed ApoE-/- mice).

    “rosuvastatin reduced mouse body weight and decreased the plasma levels of low-density lipoprotein (LDL) and total cholesterol (TC)”

    Animalshigh-fat diet-fed ApoE-/- miceintragastric administration

    Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway

    PloS one

Major adverse cardiovascular events

no changein humans2HR 0.87

2 studies
  1. Atorvastatin showed no clear effect on major adverse cardiovascular events in humans (3 (5.4%) vs 2 (3.6%)).

    “Within 7 days, MACE occurred in two patients (3.6%) in the placebo group and three patients (5.4%) in the statin group (P=1.00).”

    Human trial7 days postoperativelyn = 112

    The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial

    Research in heart yield and translational medicine

  2. Rosuvastatin was not clearly linked with major adverse cardiovascular events in humans (primary biliary cholangitis) (HR, 0.870 [95% CI, 0.740–1.023]; p = 0.091).

    “major adverse cardiovascular events (MACE) (HR, 0.870 [95% CI, 0.740–1.023]; p = 0.091)”

    Humansprimary biliary cholangitis≥ 20 mg5-year

    High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis

    BMC gastroenterology

More on Major adverse cardiovascular events

All 329

What is statins linked with?

220

Studies link statins with 220 measures, most often mortality (29 studies), major adverse cardiovascular events (10) and cardiovascular disease (10).

Mortality

downin humans29HR 0.098–0.97

29 studies
  1. Statins are associated with mortality in humans (9.6% vs. 19.2%; HR 0.55, 95% CI 0.39-0.79).

    “Over 90 days, statin therapy was associated with lower all-cause mortality (9.6% vs. 19.2%; HR 0.55, 95% CI 0.39-0.79).”

    Humansatrial fibrillation with ischemic stroke despite continuous oral anticoagulation; statin therapy at discharge90 daysn = 1,442

    Beyond anticoagulation: Statin therapy and 90-day mortality after breakthrough ischemic stroke in atrial fibrillation

    Therapeutic advances in neurological disorders

  2. Statins are associated with mortality in humans (12.7% vs 19.4%; RR 0.65, 95% CI 0.47-0.91; p=0.009).

    “At 5 years, statin initiation was associated with lower all-cause mortality (12.7% vs 19.4%; RR 0.65, 95% CI 0.47-0.91; p=0.009)”

    HumansNewly documented incidental coronary artery calcium; statin initiation within 60 days versus no initiation, after propensity matching5 years

    Incidental Coronary Artery Calcification on Chest CT- Statin Treatment Gaps and Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

  3. Statins are associated with mortality in humans (Patients with abdominal aortic aneurysms; adjusted analysis) (HR=0.73, p=0.02).

    “Adjusted analyses showed statins (HR=0.73, p=0.02), but not antiplatelets or anticoagulants, were associated with reduced risk of mortality.”

    HumansPatients with abdominal aortic aneurysms; adjusted analysisMean follow-up of 1.8 years73% malesn = 886

    Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms

    Annals of vascular surgery

  4. Statins are associated with mortality in humans (Cardiometabolic HFpEF) (HR 0.55, 95% CI 0.35–0.86).

    “Statin use (HR = 0.55, 95% CI 0.35-0.86) and metformin (HR = 0.19, 95% CI 0.05-0.78) showed significant protective effects overall.”

    HumansCardiometabolic HFpEFn = 1,158

    Prognosis and treatment response in cardiometabolic HFpEF: deep learning-based phenomapping with a pragmatic clinical classifier

    ESC Congress 2026 abstract

  5. Statins are associated with mortality in humans (Newly diagnosed heart failure; baseline CRP <2 mg/L; compared with statin nonusers) (HR 0.45, 95% CI 0.41–0.50).

    “Statin therapy was also associated with lower all-cause mortality in both CRP strata”

    HumansNewly diagnosed heart failure; baseline CRP <2 mg/L; compared with statin nonusers≥90 consecutive days after HF diagnosis

    Statins tied to survival in new heart failure inpatients in Hong Kong

    ESC Congress 2026 abstract

  6. Statins are linked with a lower risk of mortality in humans (non-ischemic acute myocardial injury) (HR 0.79, 95% CI 0.75–0.84).

    “In fully adjusted models, statin use was independently associated with lower 1-year all-cause mortality in both cohorts (development: HR 0.79, 95% CI 0.75–0.84”

    Humansnon-ischemic acute myocardial injury1 year

    Statin use linked to lower mortality after heart muscle injury

    ESC Congress 2026 abstract

  7. Statins are associated with mortality in humans (advanced carotid artery atherosclerosis).

    “Mortality (from any cause) was significantly lower in men treated with statins.”

    Humansadvanced carotid artery atherosclerosismales

    Personalized Prevention of Cardiovascular Diseases Through Measurement of Plaque Burden in the Carotid Artery

    Cardiology research

  8. Statins are associated with mortality in humans (Patients with CKD G5D following an ASCVD event; statin initiators versus non-initiators) (At four years: risk difference -6.2% (95% CI -10.2 to -2.2), relative risk 0.88 (95% CI 0.81–0.96); mean survival gain 69 days at five years (95% CI 14–125) and 135 days at ten years (95% CI 31–239)).

    “During the ten years of follow-up, statin use was associated with a reduced risk of mortality.”

    HumansPatients with CKD G5D following an ASCVD event; statin initiators versus non-initiatorsTen years67% malesn = 5,534

    Statins linked to survival on dialysis after cardiovascular events

    Kidney international

  9. Statins are linked with a lower risk of mortality in humans (long-term survivors of nasopharyngeal cancer) (HR 0.71, p < 0.001).

    “After adjusting for immortal time bias, the hazard ratio for overall survival was 0.71 (p < 0.001).”

    Humanslong-term survivors of nasopharyngeal cancern = 7,872

    Statins linked to lower death risk in nasopharyngeal cancer survivors

    The Lancet regional health. Western Pacific

  10. Statins are linked with a lower risk of mortality in humans with CHD (52.0% vs. 72.8%).

    “statin users with CHD exhibited significantly lower all-cause, cardiac, and cancer-related mortality proportions compared to non-users”

    Humanswith CHD

    Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease

    Archives of gerontology and geriatrics

All 30

Major adverse cardiovascular events

downin humans8upin humans2RR 0.55–1.21

10 studies
  1. Rosuvastatin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with atorvastatin) (RR 1.21, 95% CI 0.79–1.85; P = 0.372).

    “rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372)”

    HumansACS and multivessel coronary disease; compared with atorvastatin3 monthsn = 277

    Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

    PloS one

  2. Statins are associated with major adverse cardiovascular events in humans (17.9% vs 24.3%; RR 0.74, 95% CI 0.56-0.96; p=0.025).

    “and MACE (17.9% vs 24.3%; RR 0.74, 95% CI 0.56-0.96; p=0.025).”

    HumansNewly documented incidental coronary artery calcium; statin initiation within 60 days versus no initiation, after propensity matching5 years

    Incidental Coronary Artery Calcification on Chest CT- Statin Treatment Gaps and Cardiovascular Outcomes

    AHA Scientific Sessions 2026 abstract

  3. Statins are associated with major adverse cardiovascular events in humans (Adherent patients with uncomplicated hypertension; per-protocol sensitivity analysis) (HR 0.28, 95% CI 0.11–0.70).

    “adherence to renin-angiotensin system inhibitors and statins was associated with significantly lower risk of MACE”

    HumansAdherent patients with uncomplicated hypertension; per-protocol sensitivity analysisMedian follow-up of 52 months

    Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry

    ESC Congress 2026 abstract

  4. Rosuvastatin is associated with major adverse cardiovascular events in humans (HR 0.84, 95% CI 0.76–0.93; 624 versus 769 events).

    “rosuvastatin was associated with a lower major adverse cardiovascular events rate than atorvastatin (624 versus 769 events; hazard ratio [HR], 0.84 [95% CI, 0.76-0.93]).”

    HumansPatients with cancer receiving tyrosine kinase inhibitors; comparison with atorvastatin; time-averaged association because proportional hazards were violatedDay 30 to up to 3 years

    Association of Non-Cytochrome P450 3A4-Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score-Matched Target Trial Emulation

    Journal of the American Heart Association

  5. Statins are linked with a lower risk of major adverse cardiovascular events in new-onset T2D (HR 0.41, 95% CI 0.21-0.83).

    “statin therapy was independently associated with a lower MACE risk according to the multivariable Cox regression analysis (HR 0.41, 95% CI 0.21-0.83; p = 0.013)”

    Humansin new-onset T2Dmedian 73 monthsn = 604

    Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study

    Frontiers in endocrinology

  6. Statins are linked with a lower risk of major adverse cardiovascular events in humans after percutaneous coronary intervention for chronic coronary syndrome (HR, 0.32; 95% CI, 0.17-0.61).

    “high-intensity statin therapy reduced the incidence of the primary outcome (HR, 0.32; 95% CI, 0.17-0.61; P<0.01)”

    Humansafter percutaneous coronary intervention for chronic coronary syndromemedian follow-up of 2 yearsn = 716

    Impact of High-Intensity Statins and Low-Density Lipoprotein Cholesterol on the Outcomes of Coronary Intervention for Chronic Coronary Syndrome in Japan

    Journal of atherosclerosis and thrombosis

  7. Statins are linked with a lower risk of major adverse cardiovascular events in humans (patients with CKD and cardiomyopathy) (aOR 0.47, 95% CI 0.31-0.72).

    “regular statin therapy remained independently associated with lower MACE risk, with the strongest benefit observed in the high-dose group (adjusted odds ratio = 0.47, 95% CI: 0.31-0.72, P = .001).”

    Humanspatients with CKD and cardiomyopathy

    Association between statin use and major adverse cardiovascular events in patients with chronic kidney disease and cardiomyopathy: A retrospective case-control study

    Medicine

  8. Statins are linked with a lower risk of major adverse cardiovascular events in patients undergoing revascularization for LEAD or CAD.

    “The ratio in the overall population was 0.64 (0.430.97; P = 0.034).”

    Humansin patients undergoing revascularization for LEAD or CAD35.1 months median follow-upn = 4,861

    Efficacy of lipid lowering therapy in lower extremity artery disease and coronary artery disease undergoing revascularization

    Cardiovascular intervention and therapeutics

  9. Statins are associated with major adverse cardiovascular events in humans After ST-elevated myocardial infarction; fully adjusted analysis (12% higher chance of MACE with non-high intensity; reported interval 1.04–1.28).

    “12% (1.04, 1.28) for patients on non-high statin intensity”

    HumansAfter ST-elevated myocardial infarction; fully adjusted analysisnon-high intensity

    Association between statin intensity and adherence, and MACE in post-STEMI patients: A cohort study

    ARYA atherosclerosis

  10. Statins lower the risk of major adverse cardiovascular events in humans (acute coronary syndrome patients undergoing percutaneous coronary intervention) (RR 0.55, 95% CI 0.46-0.67).

    “Statin preloading significantly reduced MACE (RR 0.55, 95% CI 0.46-0.67; I 2 =0%)”

    Reviewacute coronary syndrome patients undergoing percutaneous coronary interventionsingle high dosen = 2,982

    Efficacy and Safety of Single High Dose Statin Preloading in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: A GRADE Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

Cardiovascular disease

downin humans8upin humans1downin silico1−56% studiesHR 0.64–0.9

10 studies
  1. Atorvastatin lowers the risk of cardiovascular disease in humans (without clinical cardiovascular disease) (HR 0.70, 95% CI 0.61–0.82, P<0.001).

    “a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”

    Human trialwithout clinical cardiovascular disease40 mg once daily5.9 yearsn = 9,971

    Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults

    The New England journal of medicine

  2. Statins are associated with cardiovascular disease in humans (type 2 diabetes mellitus) (AOR 2.21, 95% CI 1.12–4.36).

    “Low adherence to statin therapy was associated with increased odds of CVD events [AOR=2.21, 95% CI: 1.12–4.36, p=0.022].”

    Humanstype 2 diabetes mellitus

    Association Between Statin Use and Cardiovascular Events Among Type 2 Diabetes Patients in South Ethiopia: A Case-Control Study

    Research SquarePreprint

  3. Statins are linked with a lower risk of cardiovascular disease in humans (at SCORE2-OP of ~16% in adults aged 70-89 without diabetes) (HR=0.90 [0.84-0.96]).

    “with a protective association becoming stable around a SCORE2-OP of 16% (HR=0.90 [0.84-0.96]).”

    Humansat SCORE2-OP of ~16% in adults aged 70-89 without diabetesn = 167,360

    SCORE2-OP-guided statin initiation for primary prevention in adults aged 70-89 years without diabetes: evidence for age-specific risk thresholds

    European journal of preventive cardiology

  4. Statins are linked with a lower risk of cardiovascular disease in humans (type 2 diabetes, emulated nested target trials) (HR 0.69 (95% CI 0.65–0.75)).

    “a significant reduction in the incidence of CVDs (HR 0.69 (95% CI [0.65, 0.75]; p < 0.001))”

    Humanstype 2 diabetes, emulated nested target trialsn = 30,804

    Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study

    PLoS medicine

  5. Statins are linked with a lower risk of cardiovascular disease in humans (primary prevention) (-20% new coronary events (HR 0.80, 95% CI 0.68-0.94, p = 0.008)).

    “and a 20% reduction in new coronary events (HR 0.80; 95% CI: 0.68-0.94; p = 0.008).”

    Humansprimary prevention4-year mean follow-upn = 15,745

    Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study

    Journal of the American Geriatrics Society

  6. Statins lower the risk of cardiovascular disease in individuals with migraines.

    “Considering the increased cardiovascular risk in migraine sufferers compared with those without migraine, statins may play a beneficial role in both migraine management and cardiovascular risk reduction.”

    Reviewin individuals with migraines

    A Review of the Vascular Pathophysiology of Migraine: Should We Consider Statins as a Treatment Option?

    Current vascular pharmacology

  7. Statins lower the risk of cardiovascular disease in humans.

    “Statins reduce atherosclerotic cardiovascular events in women and men, with no consistent evidence of treatment-effect heterogeneity by sex.”

    Review

    Inflammation, Statin Pleiotropy, and Cardiovascular Prevention in Women: Established Evidence, Biological Plausibility, and Knowledge Gaps

    Journal of cardiovascular development and disease

  8. Statins lower the risk of cardiovascular disease in humans (55.56% of studies).

    “Ten studies (55.56%) supported statin use, emphasizing cardiovascular benefits.”

    Review

    Recommendations Regarding Statin Therapy in Adults Over 70 Years

    Revista Salud Bosque

  9. Statins lower the risk of cardiovascular disease in silico (lifetime simulation) (7.5% (6.6%-8.5%) to 11.5% (10.2%-12.8%)).

    “Over lifetime, statin treatment reduced major vascular event [7.5% (6.6%-8.5%) to 11.5% (10.2%-12.8%)]”

    In silicolifetime simulation

    Model projects higher lifetime healthcare use with statins

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

  10. Pitavastatin lowers the risk of cardiovascular disease in humans (REPRIEVE trial) (36% reduction; HR 0.64, 95% CI 0.48-0.84).

    “The REPRIEVE trial demonstrated a 36% reduction in cardiovascular risk with pitavastatin (HR 0.64, 95% CI 0.48-0.84)”

    ReviewREPRIEVE trial

    The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review

    Microorganisms

More on Cardiovascular disease

Type 2 diabetes

upin humans8downin humans1RR 2.13

9 studies
  1. Statins are linked with a higher risk of type 2 diabetes in humans (Elevated LDL-C; sustained statin therapy versus no statin therapy) (1 year: RD 2.2% (95% CI 1.6%, 3.0%), RR 2.13 (95% CI 1.80, 2.55); 5 years: RD 3.0% (95% CI 0.7%, 4.9%), RR 1.37 (95% CI 1.09, 1.62)).

    “Among young adults with elevated LDL-C, sustained statin therapy increased the risk of diabetes during early follow-up, particularly among those with baseline HbA1c in the prediabetes range.”

    HumansElevated LDL-C; sustained statin therapy versus no statin therapy1 and 5 years

    Risk of Diabetes Following Sustained Statin Therapy Among Young Adults with Elevated Low-Density Lipoprotein Cholesterol

    AHA Scientific Sessions 2026 abstract

  2. Statins are linked with a higher risk of type 2 diabetes in statin initiators aged 70-89 without baseline diabetes (HR 1.07 [1.02-1.12]).

    “A mild significant increase of type 2 diabetes was observed in statin initiators (1.07 [1.02-1.12]).”

    Humansin statin initiators aged 70-89 without baseline diabetesn = 167,360

    SCORE2-OP-guided statin initiation for primary prevention in adults aged 70-89 years without diabetes: evidence for age-specific risk thresholds

    European journal of preventive cardiology

  3. Pitavastatin is linked with a lower risk of type 2 diabetes in humans (compared with atorvastatin in elderly ASCVD patients) (odds ratio = 0.212).

    “Multivariate logistic regression analysis confirmed pitavastatin as a protective factor against new-onset diabetes (odds ratio = 0.212, p = 0.018).”

    Humanscompared with atorvastatin in elderly ASCVD patients4 mg/day12 monthsn = 126

    Association of Pitavastatin Versus Atorvastatin Therapy With Glycaemic Control and New-Onset Diabetes in Older Adults With Atherosclerotic Cardiovascular Disease

    British journal of hospital medicine (London, England : 2005)

  4. Simvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.15, 95% CI 1.06-1.20).

    “simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

  5. Pravastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.19, 95% CI 1.02-1.38).

    “pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

  6. Rosuvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (adjusted HR 1.07, 95% CI 1.01-1.14).

    “rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

  7. Statins raise the risk of type 2 diabetes in humans (particularly rosuvastatin and atorvastatin).

    “Statins were associated with an increased risk of new-onset diabetes, particularly rosuvastatin and atorvastatin”

    Reviewparticularly rosuvastatin and atorvastatin

    Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses

    European cardiology

  8. Statins raise the risk of type 2 diabetes in humans (dose-dependent exposure).

    “Statins cause a dose-dependent increase in new-onset type 2 diabetes”

    Reviewdose-dependent exposure

    Manufactured Risk: Cholesterol Threshold Inflation, Statin Expansion, and the Contested Cardiovascular and Neuropsychiatric Costs

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  9. Statins raise the risk of type 2 diabetes in postmenopausal women and middle-aged men (OR up to 1.48).

    “new-onset diabetes and glycemic progression were repeatedly associated with statin exposure, with odds ratios up to 1.48 in postmenopausal women”

    Reviewin postmenopausal women and middle-aged menfemales

    Statin Medication: Scoping Review with ☸SAIMSARA

    SAIMSARA Journal

  10. Atorvastatin raises the risk of type 2 diabetes in humans (compared to agents such as pravastatin or pitavastatin).

    “High-intensity statins like atorvastatin and rosuvastatin carry a greater risk compared to agents such as pravastatin or pitavastatin.”

    Reviewcompared to agents such as pravastatin or pitavastatin

    Statin Induced New-onset Diabetes Mellitus - A Narrative Review

    Journal of community hospital internal medicine perspectives

All 12

More on Type 2 diabetes

Alzheimer's disease

downin humans7HR 0.72–0.882

7 studies
  1. Rosuvastatin is associated with Alzheimer's disease in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.78, 95% CI 0.72–0.83; incidence 0.5% vs 0.6%; ARD -0.18%, 95% CI -0.22 to -0.15).

    “Rosuvastatin use was also associated with lower risks of Alzheimer dementia”

    Humanstype 2 diabetes; compared with atorvastatin users

    Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes

    AHA Scientific Sessions 2026 abstract

  2. Statins are associated with Alzheimer's disease in humans (HR 0.72, 95% CI 0.52-0.98).

    “statin use was associated with a reduced risk of AD (HR = 0.72, 95% CI: 0.52-0.98; p < 0.05)”

    HumansMedian follow-up of 9.24 yearsn = 502,401

    Association of statin use with reduced risk of Alzheimer's disease: findings in UK Biobank

    Frontiers in aging neuroscience

  3. Statins are linked with a lower risk of Alzheimer's disease in humans (stroke survivors) (HR 0.882, 95% CI 0.826-0.943).

    “High-intensity therapy was associated with lower risk of AD (HR 0.882, 95% CI 0.826-0.943; P < 0.001)”

    Humansstroke survivors5 years

    Neurocognitive outcomes and survival with high- vs low-intensity statins in stroke survivors: A propensity score-matched cohort (2010-2025)

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

  4. Statins are associated with Alzheimer's disease in humans (Dyslipidemia and no prior Alzheimer's disease diagnosis) (RR = 0.69).

    “Statin exposure was associated with a substantially lower risk of incident AD compared with non-exposure (RR = 0.69)”

    HumansDyslipidemia and no prior Alzheimer's disease diagnosis

    Alzheimer's disease in patients prescribed statins: A real-world data analysis of U.S. patient health records

    Journal of Alzheimer's disease : JAD

  5. Statins are linked with a lower risk of Alzheimer's disease in humans (high non-APOE PRS) (aRD -5.0‰, 95% CI: -8.2‰ to -0.2‰).

    “Participants with high non-APOE PRS showed cognitive benefit (all-cause dementia: aRD -5.9‰, 95% CI: -8.1‰ to 1.2‰; AD: aRD -5.0‰, 95% CI: -8.2‰ to -0.2‰).”

    Humanshigh non-APOE PRS

    The heterogeneous treatment effects of statins on dementia: a target trial emulation with causal machine learning using integrated genetic and real-world data

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  6. Statins are linked with a lower risk of Alzheimer's disease in humans (univariable Mendelian randomization, inverse variance weighting).

    “IVW-MR indicated statin medication significantly reduced AD risk but increased ADD and DLB risk.”

    Humansunivariable Mendelian randomization, inverse variance weighting

    Statins cut Alzheimer's risk but raise other dementia risks

    Journal of Alzheimer's disease reports

  7. Statins lower the risk of Alzheimer's disease in humans (long-term use; hedged as observational association).

    “long-term statin use may be associated with a reduced risk of incident PD and AD”

    Reviewlong-term use; hedged as observational associationlong-term

    The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence

    Pharmacology research & perspectives

More on Alzheimer's disease

Cardiovascular events

downin humans4RR 0.81

4 studies
  1. Statins lower the risk of cardiovascular events in humans (coronary atherosclerosis).

    “Statins, ezetimibe, bempedoic acid and PCSK9 monoclonal antibodies reduce cardiovascular events by lowering atherogenic lipoprotein exposure.”

    Reviewcoronary atherosclerosis

    Pharmacotherapy for coronary atherosclerosis: from lipid lowering to plaque stabilization and repair

    Frontiers in cardiovascular medicine

  2. Pravastatin lowers the risk of cardiovascular events in humans (Prediabetes with a history of myocardial infarction or unstable angina) (RR 0.81, 95% CI 0.70–0.95, p = 0.008).

    “pravastatin significantly reduced cardiovascular events in patients with prediabetes with a history of myocardial infarction or unstable angina”

    ReviewPrediabetes with a history of myocardial infarction or unstable angina

    Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials

    Medical sciences (Basel, Switzerland)

  3. Atorvastatin lowers the risk of cardiovascular events in humans.

    “Multiple large trials have shown that atorvastatin achieves concurrent control of lipids and inflammation, accompanied by reductions in cardiovascular events.”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

  4. Statins lower the risk of cardiovascular events in humans (high cardiovascular risk).

    “therapy with statins leads to a reduction in the incidence of recurrent cardiovascular events, especially in elderly patients”

    Reviewhigh cardiovascular risk

    Assessment of the high-intensity statin therapy impact on the incidence of recurrent myocardial infarction in patients at the high cardiovascular risk

    Russian Journal of Preventive Medicine

Dementia

downin humans2mixedin humans1upin humans1HR 0.954–2.22

4 studies
  1. Statins are associated with dementia in humans (All of Us Research Program discovery cohort; self-identified as White) (adjusted HR 2.22, 95% CI 2.02–2.44).

    “Statin use was associated with significantly increased dementia risk in both cohorts (discovery: adjusted HR 2.22, 95% CI 2.02–2.44; replication: adjusted HR 2.54, 95% CI 1.98–3.33).”

    HumansAll of Us Research Program discovery cohort; self-identified as White2006 through 2023n = 83,355

    Statin use linked to higher dementia risk in two cohorts

    Frontiers in pharmacology

  2. Statins are linked with a lower risk of dementia in humans within ≤ 1 year after type 2 diabetes diagnosis vs no statin within 5 years (-15% relative risk (95% CI 9%-21%)).

    “early statin treatment was associated with 15% lower relative risk of dementia at 10 years (95% confidence interval: 9%-21%)”

    Humanswithin ≤ 1 year after type 2 diabetes diagnosis vs no statin within 5 years10 years

    Early statin use links to lower dementia risk in diabetes

    The Lancet regional health. Europe

  3. Statins are linked with a lower risk of dementia in humans (stroke survivors) (HR 0.954, 95% CI 0.923-0.986).

    “Over 5 years, incident dementia occurred in 6.6% of the high-intensity group (6,816/103,208) vs 6.9% of the low/moderate group (7,104/103,208) (HR 0.954, 95% CI 0.923-0.986; P = 0.005).”

    Humansstroke survivors5 years

    Neurocognitive outcomes and survival with high- vs low-intensity statins in stroke survivors: A propensity score-matched cohort (2010-2025)

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

  4. Statins are associated with dementia in humans.

    “subsequent studies have challenged this association, with some suggesting even a protective effect.”

    Review

    Beyond Lipid-Lowering and Stroke Prevention: Unraveling the Role of Statins in Neurological Diseases

    Metabolites

More on Dementia

LDL cholesterol

downin humans3

3 studies
  1. Statins are associated with LDL cholesterol in humans (250 mg/dL at admission; 85 mg/dL at one month).

    “low-density lipoprotein cholesterol had decreased to 85 mg/dL following statin therapy and the reported discontinuation of AAS use.”

    Human trialfollowing myocardial infarction, with reported discontinuation of anabolic-androgenic steroid useone monthmales

    Very Young ST-Segment Elevation Myocardial Infarction Associated With Chronic Nonmedical Anabolic-Androgenic Steroid Use: A Case Report

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

  2. Statins are associated with LDL cholesterol in humans (LDL-C reductions: 57.3% vs 38.2% at 3 months; 58.5% vs 42.9% at 9 months; 54.3% vs 46.7% at 15 months; all p<0.001).

    “Patients receiving statin±ezetimibe showed greater LDL-C reduction compared to those not on combination therapy”

    HumansConcomitant statins with or without ezetimibe during inclisiran treatment, compared with no combination therapy3, 9, and 15 months

    Long term efficacy and adherence of inclisiran in real-world clinical practice: insights from the CHOLINET Registry

    ESC Congress 2026 abstract

  3. Atorvastatin is associated with LDL cholesterol in humans (Compared with simvastatin in routine primary health care).

    “Rosuvastatin and atorvastatin were associated with greater LDL-cholesterol reduction compared with simvastatin in primary health care.”

    HumansCompared with simvastatin in routine primary health careat least three monthsn = 1,100

    LDL-CHOLESTEROL LOWERING WITH ATORVASTATIN, ROSUVASTATIN AND SIMVASTATIN: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY

    Georgian medical news

  4. Rosuvastatin is associated with LDL cholesterol in humans (Compared with simvastatin in routine primary health care).

    “Rosuvastatin and atorvastatin were associated with greater LDL-cholesterol reduction compared with simvastatin in primary health care.”

    HumansCompared with simvastatin in routine primary health careat least three monthsn = 1,100

    LDL-CHOLESTEROL LOWERING WITH ATORVASTATIN, ROSUVASTATIN AND SIMVASTATIN: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY

    Georgian medical news

More on LDL cholesterol

Rhabdomyolysis

upin humans3

3 studies
  1. Rosuvastatin is associated with rhabdomyolysis in humans (polypharmacy; adverse reaction classified as probable).

    “We present a probable case of rosuvastatin-associated rhabdomyolysis causing stage 3 acute kidney injury requiring hemodialysis in an 87-year-old woman with polypharmacy”

    Humanspolypharmacy; adverse reaction classified as probable20 mg/day20 daysfemales

    Severe Rosuvastatin-Associated Rhabdomyolysis and Dialysis-Requiring Acute Kidney Injury in an Octogenarian Patient: A Case Report

    The American journal of case reports

  2. Rosuvastatin is associated with rhabdomyolysis in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.

    “We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”

    HumansDuring concomitant ticagrelor therapy after percutaneous coronary intervention40 mg once dailyOne monthfemales

    Severe Rhabdomyolysis and Acute Kidney Injury Following Rosuvastatin Reinitiation During Ticagrelor Therapy: A Case Report and Literature Review

    Cureus

  3. Statins are linked with a higher risk of rhabdomyolysis in patients with mitochondrial myopathy and McArdle disease (4 patients).

    “Rhabdomyolysis occurred in 4 patients (1 with mitochondrial myopathy and 3 with McArdle disease).”

    Humansin patients with mitochondrial myopathy and McArdle diseasen = 135

    Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability

    Neurology. Clinical practice

More on Rhabdomyolysis

Cardiovascular mortality

downin humans3HR 0.54–0.89

3 studies
  1. Statins are associated with cardiovascular mortality in humans (Cardiovascular death–free proportion 1.0 in patients and unaffected siblings versus 0.93 (95% CI 0.90–0.95) in affected parents; P=0.009).

    “The cumulative cardiovascular death–free proportion was both 1.0 among patients with FH and their unaffected siblings, and 0.93”

    HumansPatients with familial hypercholesterolemia treated from childhood compared with affected parents without childhood statin treatment

    Childhood statins linked to lower adult cardiovascular risk

    Arteriosclerosis, thrombosis, and vascular biology

  2. Atorvastatin is linked with a lower risk of cardiovascular mortality in humans (chemotherapy-treated cancer) (3.3% vs. 6.0%, HR 0.54 (95% CI 0.29–1.02)).

    “trend toward lower cardiovascular mortality (3.3% vs. 6.0%; HR 0.54; 95% CI 0.29–1.02; p=0.058)”

    Humanschemotherapy-treated cancerheart40-80 mg/day5 years61% femalesn = 800

    Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients

    ESC Congress 2026 abstract

  3. Statins are linked with a lower risk of cardiovascular mortality in humans (non-ischemic acute myocardial injury) (HR 0.89, 95% CI 0.82–0.96).

    “statin use was also associated with reduced cardiovascular death (HR 0.89, 95% CI 0.82–0.96)”

    Humansnon-ischemic acute myocardial injury1 year

    Statin use linked to lower mortality after heart muscle injury

    ESC Congress 2026 abstract

Cardiovascular and cerebrovascular events

downin humans1

1 study
  1. Atorvastatin lowers the risk of cardiovascular and cerebrovascular events in humans (patients with carotid plaque; compared with no statin therapy) (22 events among 234 statin-treated patients versus 36 among 202 controls; log-rank P=0.0107).

    “22 events occurred among 234 patients in the statin group and 36 among 202 patients in the control group”

    Human trialpatients with carotid plaque; compared with no statin therapy20 mg dailyextended follow-up beyond 24 months through 2025

    Effect of atorvastatin on carotid plaque progression-a prospective study

    Frontiers in cardiovascular medicine

Circulating protein abundance

mixedin humans1

1 study
  1. Atorvastatin is associated with circulating protein abundance in humans (statin-intolerant patients; placebo-controlled crossover) (243/1,037 proteins (23.4%): 140 upregulated, 103 downregulated; 57 significant after adjustment: 8 upregulated, 49 downregulated).

    “atorvastatin significantly affected 243 out of 1,037 proteins (23.4%) in the unadjusted model (FDR q<0.05; 140 upregulated, 103 downregulated).”

    Human trialstatin-intolerant patients; placebo-controlled crossoverplasma20 mg54% femalesn = 133

    Atorvastatin Broadly Alters the Circulating Proteome in Statin-Intolerant Patients: A Proteomic Substudy of the GAUSS-3 Randomized Clinical Trial

    AHA Scientific Sessions 2026 abstract

More on Circulating protein abundance

Noncalcified coronary plaque volume

downin humans1

1 study
  1. Statins are associated with noncalcified coronary plaque volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = -9.83, SE = 1.64).

    “alongside regression of noncalcified plaque (β = -9.83, SE = 1.64; P < 0.001)”

    Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338

    Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention: The CAUGHT-CAD Trial

    JACC. Cardiovascular imaging

More on Noncalcified coronary plaque volume

High-density coronary calcium volume

upin humans1

1 study
  1. Statins are associated with high-density coronary calcium volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = 0.79, SE = 0.24).

    “and high-density (β = 0.79, SE = 0.24; P = 0.001) calcium, alongside regression of noncalcified plaque”

    Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338

    Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention: The CAUGHT-CAD Trial

    JACC. Cardiovascular imaging

More on High-density coronary calcium volume

Intermediate-density coronary calcium volume

upin humans1

1 study
  1. Statins are associated with intermediate-density coronary calcium volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = 0.89, SE = 0.39).

    “Statin treatment was associated with greater progression in intermediate-density (β = 0.89, SE = 0.39; P = 0.02)”

    Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338

    Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention: The CAUGHT-CAD Trial

    JACC. Cardiovascular imaging

More on Intermediate-density coronary calcium volume

All 220

What acts on statins?

4

Studies name 4 things that act on statins, among them healthy aging program, beta-lactams and prac recommendations.

Healthy aging program

upin humans1

1 study
  1. Healthy aging program is linked with higher statins in humans (people living with HIV) (from 65.6% to 70.0%).

    “Statin utilization increased from 65.6% at baseline to 70.0% at 12 months”

    Humanspeople living with HIVn = 317

    A Multidisciplinary Healthy Aging Program in Comprehensive HIV Care: Multidomain Screening, Clinical Interventions, and Cardiometabolic Risk Management

    Viruses

More on Healthy aging program

Beta-lactams

downin humans1

1 study
  1. Beta-lactams are linked with rosuvastatin in humans (patients with CHD on statin therapy).

    “concomitant β-lactam use impairs rosuvastatin efficacy in patients with CHD”

    Humanspatients with CHD on statin therapy

    Role of the Gut Microbiome in Modulating Interactions Between β-Lactam Antibiotics and Statins in Coronary Heart Disease

    Journal of cardiovascular pharmacology

More on Beta-lactams

Prac recommendations

upin humans1

1 study
  1. Prac recommendations are linked with higher statins in humans (rheumatoid arthritis) (8.25% vs. 11.1%).

    “and increased statin use (8.25% vs. 11.1%; p = 0.05).”

    Humansrheumatoid arthritisn = 4,376

    The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI

    Journal of personalized medicine

More on Prac recommendations

Risk-enhancing factors

no changein humans1

1 study
  1. risk-enhancing factors were not clearly linked with statins in borderline 10-year ASCVD risk (5-7.4%) and diabetes categories.

    “but not borderline ASCVD risk (5-7.4%) or diabetes categories”

    Humansin borderline 10-year ASCVD risk (5-7.4%) and diabetes categories

    Prevalence of Atherosclerotic Cardiovascular Disease Risk-Enhancing Factors and Their Association with Primary Prevention Statin Use

    Journal of general internal medicine

Trials

270 of 1,470 about aging

Who is developing statins?

3 companies: Organon, Merck Sharp & Dohme and AstraZeneca.

Companies
  • OrganonsimvastatinPhase 4atherosclerosis, hypercholesterolemia
  • Merck Sharp & DohmerosuvastatinPhase 3hyperlipidemia
  • AstraZenecarosuvastatinPhase 3hypercholesterolemia, high cholesterol

Trial sponsors

Funding

72 grants since 2016

National Heart, Lung, and Blood Institute$25.5MUS Department of Veterans AffairsNational Institute of Neurological Disorders and Stroke$20.6M

How this record changed

  1. Lipoprotein(a) · 1 finding

  2. Summary rewritten as its findings changed.

    As it read before

    Simvastatin extends fly lifespan and pravastatin reduces senescence in human cells, with both results repeated by independent labs, although a finding shows shorter fly lifespan. Independent labs also report associations between statins and lower human mortality, while human studies report opposing dementia associations. Some papers declare ties to statin developers, which also sponsor trials.

  3. Summary rewritten as its findings changed.

    As it read before

    Independent labs report longer fly lifespan with simvastatin and reduced senescence in human cells with pravastatin, but fly lifespan results also point the other way. A human cohort links statins with lower mortality after noncardiac surgery; other cohorts link them with higher diabetes incidence in normoglycemic people. Some human papers declare ties to companies developing statins.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs link statins with lower human mortality and simvastatin with longer fly lifespan, but fly lifespan and human dementia results disagree. Of registered trials, 108 concern aging; 749 across all uses ended over a year ago without posted results or citing papers. Authors declare developer ties, and developers sponsor 391 trials across all uses.

  5. Summary rewritten as its findings changed.

    As it read before

    Independent labs report longer fly lifespan with simvastatin and lower human mortality with statins, but other studies report shorter fly lifespan or no human mortality effect. There are 101 aging-related registered trials; 749 trials across all uses ended over a year ago without posted results or citing papers. Developers sponsor 394 trials across uses, and 20 human papers declare developer ties.

  6. Summary rewritten as its findings changed.

    As it read before

    Simvastatin extends fly lifespan across independent labs but not in a worm study; independent labs also associate statin use with lower human mortality. There are 91 aging-related trials; across all uses, 730 trials ended over a year ago without posted results or citing papers. Developer companies sponsor 378 trials across all uses.

Latest

Neurology

Statins not linked to lower dementia risk in older male veterans

Estimated 10-year dementia risks were 9.4% with statins and 9.6% without them in an analysis of veterans’ health records.Estimated 10-year dementia risks were 9.4% with statins and 9.6% without them in an analysis of veterans’ health records.

Cohort studyStatins

See all 2,874 papers on statins